概述

  • 产品名称Anti-FCP1抗体
    参阅全部 FCP1 一抗
  • 描述
    小鼠单克隆抗体to FCP1
  • 经测试应用适用于: WB, ELISAmore details
  • 种属反应性
    与反应: Human
  • 免疫原

    Recombinant fragment corresponding to the internal amino acids 332-431 (PPGSRESQTR KKVNHSRGTE VSEPSPPVRD PEGVTQAPGV EPSNGLEKPA RELNGSEAAT PRDSPRPGKP DERDIWPPAQ APTSSQELAG APEPQGSCAQ) of human FCP1 (AAH63447) linked to a proprietary tag.

  • 阳性对照
    • HepG2 cell lysate

性能

相关产品

应用

Our Abpromise guarantee covers the use of ab88479 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
WB Use a concentration of 1 - 5 µg/ml. Predicted molecular weight: 104 kDa.
ELISA Use at an assay dependent dilution.

靶标

  • 功能Processively dephosphorylates 'Ser-2' and 'Ser-5' of the heptad repeats YSPTSPS in the C-terminal domain of the largest RNA polymerase II subunit. This promotes the activity of RNA polymerase II.
  • 组织特异性Ubiquitously expressed. Isoform 3 is expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney and placenta.
  • 疾病相关Defects in CTDP1 are a cause of congenital cataracts facial dysmorphism and neuropathy syndrome (CCFDN) [MIM:604168]. CCFDN is an autosomal recessive developmental disorder that occurs in an endogamous group of Vlax Roma (Gypsies). The syndrome is characterized by a complex clinical phenotype with seemingly unrelated features involving multiple organs and systems. Developmental abnormalities include congenital cataracts and microcorneae, hypomyelination of the peripheral nervous system, impaired physical growth, delayed early motor and intellectual development, facial dysmorphism and hypogonadism. Central nervous system involvement, with cerebral and spinal cord atrophy, may be the result of disrupted development with superimposed degenerative changes. Affected individuals are prone to severe rhabdomyolysis after viral infections and to serious complications related to general anesthesia (such as pulmonary edema and epileptic seizures).
  • 序列相似性Contains 1 BRCT domain.
    Contains 1 FCP1 homology domain.
  • 翻译后修饰Phosphorylated. In the presence of TFIIF, the phosphorylated form has an increased CTD phosphatase activity. The phosphorylation is required for the physical interaction with GTF2F1.
  • 细胞定位Nucleus.
  • Information by UniProt
  • 数据库链接
  • 别名
    • CCFDN antibody
    • CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1 antibody
    • CTD of POLR2A, phosphatase of, subunit 1 antibody
    • CTDP1 antibody
    • CTDP1_HUMAN antibody
    • EC 3.1.3.16 antibody
    • RNA polymerase II subunit A C terminal domain phosphatase antibody
    • RNA polymerase II subunit A C-terminal domain phosphatase antibody
    • Serine phosphatase FCP1a antibody
    • TFIIF associating CTD phosphatase antibody
    • TFIIF-associating CTD phosphatase 1 antibody
    • TFIIF-associating CTD phosphatase antibody
    • Transcription factor IIF-associating CTD phosphatase 1 antibody
    see all

Anti-FCP1 antibody 图像

  • Anti-FCP1 antibody (ab88479) at 5 µg/ml + tagged, recombinant fragment of human FCP1 (the immunogen) at 0.2 µg

    Predicted band size : 104 kDa
    Observed band size : 37 kDa (why is the actual band size different from the predicted?)
  • Anti-FCP1 antibody (ab88479) at 5 µg/ml + HepG2 cell lysate at 50 µg
    Developed using the ECL technique

    Predicted band size : 104 kDa
    Observed band size : 104 kDa
  • ab88479, at 10 µg/ml, detecting recombinant FCP1 (with a proprietary tag) by capture ELISA. The detection limit for ab88479 is approximately 0.03 ng/ml when used as a capture antibody.

Anti-FCP1 antibody (ab88479)参考文献

ab88479 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab88479.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"